• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

NeutraKine FLT3 Ligand Monoclonal antibody

NeutraKine FLT3 Ligand Monoclonal Antibody for ELISA, Neutralization

Host / Isotype

Mouse / IgG1

Reactivity

Human

Applications

ELISA, Neutralization

Conjugate

Unconjugated

CloneNo.

3E1A3

Cat no : 69032-1-Ig

Print datasheet

Synonyms

FL, Flt3 ligand, Flt3L, FLT3LG, SL cytokine

验证数据展示

  • Neutralization experiment of NeutraKine FLT3 Ligand using 69032-1-Ig

    Neutralization experiment of NeutraKine FLT3 Ligand using 69032-1-Ig

    Recombinant human FLT3 Ligand (Cat.NO. HZ-1151) stimulates proliferation of OCI-AML5 cells in a dose-dependent manner (blue curve, refer to bottom X-left Y). The activity of human FLT3 (1 ng/mL) is neutralized by mouse anti-human FLT3 Ligand monoclonal antibody 69032-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 0.01-0.05 μg/mL.The control mouse anti-human FLT3 Ligand monoclonal antibody 69532-1-Ig could recognize human FLT3 Ligand, but could not neutralize human FLT3 Ligand at serial does at the range of 0.12207-2000ng/mL(green curve, refer to top X-right Y).

  • ELISA experiment of Recombinant protein using 69032-1-Ig

    ELISA experiment of Recombinant protein using 69032-1-Ig

    Indirect ELISA was carried out by coating recombinant Human FLT3 Ligand (Cat.NO. HZ-1151) at 70 ng/well followed by blocking and adding serial diluted FLT3 Ligand antibody 69032-1-Ig and 69532-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.

  • Neutralization experiment of NeutraKine FLT3 Ligand using 69032-1-Ig

    Neutralization experiment of NeutraKine FLT3 Ligand using 69032-1-Ig

    Recombinant human FLT3 Ligand (Cat.NO. HZ-1151) stimulates proliferation of OCI-AML5 cells in a dose dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human FLT3 Ligand (1ng/mL HZ-1151) is neutralized by mouse anti-human FLT3 Ligand monoclonal antibody 69032-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 0.01-0.05 μg/mL.

NeutralizationOCI-AML5

产品信息

69032-1-Ig targets NeutraKine FLT3 Ligand in ELISA, Neutralization applications and shows reactivity with Human samples.

Tested Applications ELISA, Neutralization Application Description
Tested Reactivity Human
Immunogen human NeutraKine FLT3 Ligand protein HZ-1151 种属同源性预测
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Full Name fms-related tyrosine kinase 3 ligand
Synonyms FL, Flt3 ligand, Flt3L, FLT3LG, SL cytokine
Gene Symbol FLT3 Ligand
Gene ID (NCBI) 2323
Conjugate Unconjugated
Form Lyophilized Powder
Purification MethodProtein G purification
Storage Buffer Sterile PBS.
Endotoxin<0.1 EU/μg
ReconstitutionThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

背景介绍

The FMS-related tyrosine kinase 3 (FLT3) ligand (FLT3LG), a growth factor, is mainly derived from lymphocytes in the tumor microenvironment. It binds to FLT3 on DCs to enhance their differentiation and expansion. Therefore, it may assist DCs in tumor antigen presentation and antitumor immune response. In addition, mature DCs express FLT3 and proliferate massively under the trigger of FLT3LG.

This antibody is used to neutralize the bioactivity of FLT3 Ligand.